MedTrace Logo

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

NCT06773962 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-04-23

No results posted yet for this study

Summary

The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Conditions

  • Parkinson's Disease (PD)

Interventions

DRUG

TB006

IV infusion.

DRUG

Placebo

IV infusion.

Sponsors & Collaborators

  • TrueBinding, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2026-11-28
Completion
2026-11-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06773962 on ClinicalTrials.gov